-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Studies have shown that BRAF and MEK inhibitors significantly improve the prognosis of metastatic melanoma.
Studies have shown that BRAF and MEK inhibitors significantly improve the prognosis of metastatic melanoma.
Adoptive cell therapy based on tumor infiltrating lymphocytes (TILs) shows potential therapeutic value in metastatic melanoma, but it has not been studied in the field of immunity.
This is a Phase II open-label, single-arm, multi-center study, including multiple cohorts.
This is a Phase II open-label, single-arm, multi-center study, including multiple cohorts.
The study included 66 patients who received an average of 3.
Clinical benefits (ORR, DCR)
Median DOR
The median OS was 17.
The median OS was 17.
Median OS
In terms of safety, all patients had at least one treatment-related adverse event (TEAEs).
In terms of safety, all patients had at least one treatment-related adverse event (TEAEs).
Treatment-related adverse events
In summary, Lifileucel treatment is effective for metastatic melanoma, including patients who are resistant to PD1 or PDL1 inhibitors.
In summary, Lifileucel treatment is effective for metastatic melanoma, including patients who are resistant to PD1 or PDL1 inhibitors.
Original source:
Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, et al.
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
J Clin Oncol.
2021 May 12;JCO2100612.
doi: 10.
1200/JCO.
21.
00612.
Online ahead of print.
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
J Clin Oncol.
2021 May 12;JCO2100612.
doi: 10.
1200/JCO.
21.
00612.
Online ahead of print.
Leave a message here
